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Abstract
Animal models of human diseases that accurately recapitulate
clinical pathology are indispensable for understanding molecular
mechanisms and advancing preclinical studies. The Alzheimer’s
disease (AD) research community has historically used first-genera-
tion transgenic (Tg) mouse models that overexpress proteins linked
to familial AD (FAD), mutant amyloid precursor protein (APP), or
APP and presenilin (PS). These mice exhibit AD pathology, but the
overexpression paradigm may cause additional phenotypes unre-
lated to AD. Second-generation mouse models contain humanized
sequences and clinical mutations in the endogenous mouse App
gene. These mice show Ab accumulation without phenotypes
related to overexpression but are not yet a clinical recapitulation
of human AD. In this review, we evaluate different APP mouse
models of AD, and review recent studies using the second-
generation mice. We advise AD researchers to consider the
comparative strengths and limitations of each model against the
scientific and therapeutic goal of a prospective preclinical study.
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Modeling preclinical AD with APP mice
Alzheimer’s disease (AD) is the most common neurodegenerative
disease. In 2015, of the ~47 million individuals with dementia
worldwide (Prince et al, 2016), AD accounted for 50–70% of these
cases (Winblad et al, 2016). In the coming decades, global AD
prevalence is projected to reach higher epidemic levels that will
place a massive economic burden on society. Given the grim
epidemiological forecast, scientifically based strategies to prevent
AD are urgently needed, as evidenced by the fact that in the previ-
ous two decades more than 400 medication candidates failed to
reach the clinic (Mangialasche et al, 2010). This large-scale failure
by the pharmaceutical industry and biomedical research community
can be attributed to many factors, including inappropriate choice of
mouse models, wrong timing for therapeutic interventions, over-
reliance on inappropriate assays for translational studies, or lack of
precise biomarkers, most of which center on efficacy and repro-
ducibility in preclinical studies of which animal models were a criti-
cal component. In this review, we focus on the important roles that
genetically engineered mouse models have contributed to AD mech-
anistic studies and preclinical drug development. Recently, new
mouse models have been introduced to the community, and we will
summarize the construction, characteristics, and merits and demer-
its of current AD mouse models to facilitate understanding of these
tools for the design of future studies. In this aim, we will be guided
by the principle that AD is a disease that should ideally be prevented
in preclinical stages where a potential interventional window of at
least 20 years exists before dementia clinically manifests (Funato
et al, 1998; Bateman et al, 2012).
Clinically, AD is characterized by early memory deficits followed
by a decline in other cognitive functions (Scheltens et al, 2016;
Winblad et al, 2016). The pathology of AD begins before overt
cognitive symptoms and includes the accumulation of amyloid b
peptide (Ab) as extracellular plaques, hyper-phosphorylated tau as
intracellular neurofibrillary tangles (NFTs), and chronic neuroin-
flammation, followed by the loss of neuronal cells mainly in the
cerebral cortex and hippocampus (Braak & Braak, 1991; Hyman
et al, 2012). In parallel, a coordinated breakdown in vascular, astro-
glial, and oligodendrocytic responses demonstrates that AD is a
systems disorder and the roles and interactions of different cell types
in the decline of brain homeostasis and resultant dementia is a
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major research topic (De Strooper & Karran, 2016). Ab pathology is
initiated at least two decades before cortical tau pathology and the
onset of clinical symptoms (Bateman et al, 2012; Maruyama et al,
2013). After disease onset, it is increasingly difficult to treat symp-
toms after postmitotic neurons start to degenerate (Fig 1) and finely
tuned neuronal circuits and cognitive skills are not easily recovered
at later stages. Thus, the development of accurate preclinical animal
models of AD for studies of disease mechanisms and the develop-
ment of medications for early prevention and treatment are consid-
ered vital research goals in accord with the global epidemiological
status.
Sporadic late-onset AD (LOAD) accounts for more than 99% of
all cases (Campion et al, 1999), and the ratio of LOAD patients to all
AD patients continues to increase because aging is a primary risk
factor aligned with aging of the world population. Early-onset AD
(EOAD), in contrast, is predominately familial and caused by muta-
tions in genes that encode amyloid precursor protein (App), prese-
nilin-1 (PSEN1 or PS1) and presenilin-2 (PS2). Proteolytic
processing of APP by b-secretase (b-site APP cleaving enzyme 1 or
BACE1) and c-secretase generates soluble Ab fragments. c-Secretase
is a protein complex composed of PS1 or PS2, nicastrin, Aph1 and
presenilin enhancer 2 (PEN2). Most familial AD (FAD) mutations
affect processivity of c-secretase resulting in the release of longer Ab
peptides and a shift in the relative ratios of the different peptides,
including the Ab42/Ab40 ratio (Welander et al, 2009; Cha´vez-
Gutie´rrez et al, 2012). Similarly, mutations in the App gene result in
the production of longer Ab peptides that aggregate more easily
(Rosenberg et al, 2016). Interestingly, an AppA673T mutation was
claimed to reduce the risk of sporadic AD (SAD) and age-related
cognitive decline by decreasing the production of Ab (Jonsson et al,
2012), although these findings require confirmation (Wang et al,
2015) and the mutation appears to affect the biophysical properties
of Ab peptides (Benilova et al, 2014; Maloney et al, 2014). The exis-
tence of familial mutations that directly affect Ab production and
influence AD risk is often cited as evidence that Ab accumulation is
central to AD pathogenesis (amyloid cascade hypothesis: Selkoe &
Hardy, 2016).
In general, Ab and tau pathology in sporadic and familial cases
are morphologically similar, rationalizing the use of mouse models
with genetically engineered FAD mutations for understanding SAD.
However, the extent to which these models actually reproduce SAD
remains unknown. A critical factor to consider in developing and
using mouse APP models is the potential mechanism of Ab accumu-
lation. In FAD, Ab deposition is primarily caused by the increased
production of Ab>40 except for intra-Ab sequence mutations that
alter its structural properties (Selkoe & Hardy, 2016) or the Swedish
mutation that increases all Ab species by increasing cleavage at the
b-site. Whether the Iceland mutation AppA673T is protective by
decreasing Ab production (Jonsson et al, 2012) remains controver-
sial. However, because Ab degradation declines with aging poten-
tially due to a decrease in the major Ab-degrading enzyme
neprilysin (Iwata et al, 2001, 2002; Hellstro¨m-Lindahl et al, 2008)
and because Ab clearance is decreased in SAD patients
(Mawuenyega et al, 2010), Ab deposition in SAD is likely partially
caused by an aging-associated decrease in degradation/clearance of
Ab (Fig 2). In accord, increased production of Ab or its decreased
degradation/clearance might contribute to Ab accumulation in AD
(Saido & Iwata, 2006). Recent studies on the ubiquitin-proteasome
system and autophagy (Nilsson et al, 2013; Ciechanover & Kwon,
2015; Khaminets et al, 2016) point to the essential significance of
protein degradation in many diseases including AD. While
decreased Ab degradation may be dominant in SAD, most APP
mouse models have increased FAD-like production. The selection of
a mouse model for preclinical studies should consider this issue.
Various AD mouse models (Onos et al, 2015; Puzzo et al, 2015;
Drummond & Wisniewski, 2017) as well as other animal models
including rats, non-human primates, Drosophila, and Caenorhabdi-
tis elegans (Drummond & Wisniewski, 2017) have been recently
reviewed. In this review, we will focus on genetically modified APP
mouse models of AD as they are the most practical approach for
in vivo screening and validation of preventive medications at this
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Figure 1. Cortical pathology, neurological symptoms, and APP mouse
models of AD.
There are three neurological phases leading to the onset of AD and associated
cortical pathology. The first phase is preclinical AD, where Ab accumulates in
cortex without neurological symptoms. The second phase is mild cognitive
impairment (MCI), where tauopathy and neurodegeneration proceed with
predementia symptoms. The third phase is AD, where neurodegeneration
eliminates neurons and neuronal circuits in an irreversible manner with
progressively serious symptoms of dementia. As models of preclinical AD, APP-
overexpressing mice or App knock-in mice exhibit extensive Ab pathology
without tauopathy and neurodegeneration, for which there is a preventive
window of approximately two decades. Modified from Ihara and Arai (2007). The
pathology shown is from the cortex of a 9-month-old AppNL-G-F/NL-G-Fmouse. Blue:
Ab; red: microglia (Iba-1); green: astrocyte (GFAP) (Saito et al, 2014).
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time (Zahs & Ashe, 2010). In the absence of gene manipulations, no
small animal models exist at present that sufficiently or consistently
mimic clinical disease pathology for experimental and preclinical
studies of AD. Furthermore, we will focus on the preclinical stage
when the time window for effective prevention and treatment is
wider. Preclinical AD patients are cognitively normal (Bateman
et al, 2012), and likewise, model mice in parallel preclinical stages
having Ab pathology without tauopathy and neurodegeneration
should not exhibit strong cognitive impairment. However, at this
early stage, pathological alterations in Ab or tau are thought to initi-
ate disease processes including synaptic dysfunction, local damage
to spines and dendrites, and vascular pathology that are observed in
AD mouse models and presumably in presymptomatic humans
(Ashe & Zahs, 2010). There are other potential points for prevention
at this stage, such as mechanism(s) by which Ab amyloidosis affects
tauopathy or by which TREM2 (Guerreiro et al, 2013; Jonsson &
Stefansson, 2013) influences pathogenesis and these may also be
studied in mouse models for Ab pathology.
First-generation mouse models
First, a note on terminology: The term “transgenic (Tg) mice” could
be confusing because in a wide sense it means “genetically modified
mice” and because it also means mice into the host genome of
which transgene is inserted in single or multicopy number. We use
the second definition for the Tg mice in this review because knock-
in and knockout mice are different from Tg mice in that they main-
tain the original murine genomic structure except for the introduced
mutations.
Several groups generated Tg mice that overexpress APP with or
without FAD mutations using various promoters (Table 1), such as
platelet-derived growth factor-b (PDGF-b), prion protein (PrP), and
Thy1. Frequently used models include PDAPP (Games et al, 1995),
Tg2576 (Hsiao et al, 1996), APP23 (Sturchler-Pierrat et al, 1997),
J20 (Mucke et al, 2000), and TgCRND8 (Chishti et al, 2001). The
APP constructs differ among the lines: They include APP695,
APP770, and minigenes. Some mice carry more than one mutation
in the transgene, and the most commonly used mutation is the
Swedish mutation (K670N/M671L; Citron et al, 1992), which causes
the overproduction of total Ab from APP. These mice exhibit extra-
cellular Ab deposits in the brain, which are reminiscent of plaques
in human patients with some differences (refer to section “Limita-
tions of first-generation mouse models”). In addition, these mice
develop cognitive dysfunction before the appearance of amyloid
plaques in many cases. However, they are unable to recapitulate
neurofibrillary tangle (NFT) formation or neuronal loss.
APP-Tg mice recapitulate only a part of AD pathology, and
efforts were made to combine them with other mutant mice to
further reconstitute the remaining pathological hallmarks. PS1 is a
constituent of the c-secretase complex that cleaves the C terminal
fragment of APP generated by b-secretase (CTF-b) to produce Ab
(De Strooper et al, 1998). PS1 mutations cause the majority of
FAD cases (Karch et al, 2014). The overexpression of mutant PS1
or a knock-in pathogenic PSEN1 gene mutation alone did not
induce Ab pathology, presumably because the absolute amount of
pathogenic longer Ab such as Ab42 and Ab43 generated from
mouse APP was insufficient (De Strooper et al, 1995). Alternately,
mouse Ab might have low amyloidogenic potential that might be
caused by the existence of three different amino acids compared
to human Ab (Chui et al, 1999; Guo et al, 1999; Schmitz et al,
2004; Xu et al, 2015). However, the combination of these mice
with human APP-overexpressing Tg mice increased pathogenic Ab
production and conferred amyloidogenicity, which resulted in
accelerated Ab deposition, behavioral deficits, and neuronal loss.
These combinations include Tg2576 and PS1M146L Tg (Holcomb
et al, 1998), APPKM670/671NL Tg and PSA246E Tg (Borchelt et al,
1996, 1997), APP751KM670/671NL-V717I Tg and PSM146L Tg (Schmitz
et al, 2004), and APP KM670/671NL-V717I and PSEN1
M233T/L235P knock-
in (Casas et al, 2004). Oakley et al (2006) generated 5XFAD mice
carrying five FAD mutations in APP and PS1 transgenes
(APPK670N/M671L/I716V/V717I Tg and PSEN1M146L/L286V Tg) driven by
the Thy-1 promoter. These mice exhibited cerebral Ab pathology
and gliosis as early as 2 months of age, synaptic degeneration and
neuronal loss, and developed progressive cognitive deficits as early
as 4–5 months. However, the 5XFAD mice also failed to develop
NFTs despite their aggressive phenotypes and pathological changes
(refer to section “Limitations of first-generation mouse models”).
In efforts to replicate NFT pathology, crossbreeding of mutant
Tau-Tg mice with APP-Tg mice enhanced tau pathology in the
limbic system and olfactory cortex without affecting Ab pathology
(Tg2576 and JNPL3: Lewis et al, 2001; APP23 and JNPL3: Bolmont
et al, 2007). Oddo et al (2003) generated a triple Tg model, 3xTg-
AD mice, which overexpress APPswe, and TauP301L transgenes on a
PS1M146V knock-in background. The mice exhibit neuropathology
similar to AD patients, including the formation of Ab plaques and
NFTs, together with gliosis, synaptic damage, and memory deficits.
However, the introduced mutations in the Mapt gene that encode
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Figure 2. Ab proteostasis determined by the balance of production and
degradation.
The balance of anabolism and catabolism determines the steady-state quantity
of a given protein in a biological system. In FAD, increased anabolism of
pathogenic Ab (Ab42 and Ab43) in cortex results in pathological deposition. In SAD,
the causes of Ab accumulation are not fully understood, but an aging-associated
decrease in catabolism is a candidate mechanism (Saido & Iwata, 2006;
Hellström-Lindahl et al, 2008).
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Table 1. Comparison of current APP mouse models of AD.
Strain(s)
Genetic
background Promoter Mutation(s) General features
Potential
disadvantages
Suitable
applications
Single transgenic
APP-Tg
PDAPP C57B6 × DBA2 PDGF-b APPV717F Moderate behavioral
phenotype
Neuronal loss in
some models
Random integration of a
transgene
Overexpression-related
artifacts: multiple APP
fragments overproduced
No perfect negative
control mice
Artificial expression
pattern controlled by
exogenous promoters
No NFTs, a feature of
preclinical AD
Sudden death (unknown
reason): Tg2576, APP23
Cognitive impairment
often preceding Ab
accumulation
Mixed genetic
backgrounds in some cases
Analysis of Ab
production,
deposition, and
Ab-associated
neuroinflammation
Drug development
(targeting Ab
deposits and
secretases)
Analysis of behavior
if caused by Ab
Identification of CSF
biomarkers
Tg2576 B6; SJL mixed
background
hamster prion
protein (PrP)
APPKM670/671NL
APP23 C57BL/6 mouse Thy1 APPKM670/671NL
J20 C57BL/6 PDGF-b APPKM670/671NL,V717F
TgCRND8 Hybrid
C3H/He-C57BL/6
hamster prion
protein (PrP)
APPKM670/671NL,V717F
Double transgenic
APP-Tg × PSEN1-Tg
or KI
APPPS1 C57BL/6J mouse Thy1
(APP, PS1)
APPKM670/671NL
PS1I166P
Moderate behavioral
phenotype
Ab accumulation
from early stage
Neuronal loss in
some models
Random integration of a
number of transgenes in
some cases
Overexpression-related
artifacts: multiple APP
fragments overproduced
No perfect negative
control mice
Artificial expression
pattern controlled by
exogenous promoters
Multiple mutations
(APP + PS1)
Non-specific ER stress may
arise
No NFTs, a feature of
preclinical AD
Mixed backgrounds in
some cases
Complicated crossbreeding
in some cases
Analysis of Ab
production, deposition,
and Ab-associated
neuroinflammation
Drug development
(targeting Ab deposits
and secretases)
Analysis of behavior if
caused by Ab
Identification of CSF
biomarkers
Analysis of cell death,
in some cases
5XFAD (C57BL/6 × SJL)F1
and C57BL/6J
mouse Thy1.2
(APP, PS1)
APPKM670/671NL,I716V,V717I
PS1M146L,L286V
Triple transgenic 3xTg-AD C57BL/6J mouse Thy1.2
(APP, Tau)
endogenous (PS1)
APPK670N,M671L
PS1M146V
MAPTP301L
Moderate to severe
behavioral phenotype
NFT formation
Neuronal loss
Random integration of
transgenes
Overexpression-related
artifacts: multiple APP
fragments overproduced
No perfect negative
control mice
Artificial expression
pattern controlled by
exogenous promoters
Multiple mutations
(APP + PS1 + FTDP-17)
where FTDP-17mutations
are not causes of AD
Mixed genetic backgrounds
Complicated crossbreeding
Cognitive impairment
preceding Ab
accumulation
Analysis of Ab
production,
deposition, and
Ab-associated
neuroinflammation
Drug development
(targeting Ab and tau)
Analysis of behavior
if caused by Ab
and tau
Tau imaging
Identification of CSF
biomarkers
Analysis of cell
death
Single App knock-in NL-F C57BL/6J endogenous APP APPKM670/671NL,I716F Minor behavioral
phenotype
No overexpression
of APP and
byproducts except
for CTFb
Endogenous App
promoter-driven
gene expression
Presence of relevant
control mice
(NL mice) Two lines
for differential
purposes
NL-F (wild-type Ab)
NL-G-F (Arctic Ab) :
Ab accumulation
from early stage
Multiple familial AD
mutations of APP, the
interaction between
which has not been
identified
Unknown effects of Arctic
mutation
No severe behavioral
phenotypes, a feature of
preclinical AD
No NFTs or neuronal loss,
a feature of preclinical AD
Genomic homozygosity in
order to accelerate
pathology and to remove
murine endogenous Ab
(heterozygous mice
accumulate Ab, but take
longer than homozygous
mice.)
Overproduction of CTFb
Analysis of Ab
production,
deposition, and
Ab-associated
neuroinflammation
Analysis of
molecular pathways
Analysis of neural
network
Omics analysis
Reverse genetic
analysis using the
knockout and
knock-in mice
Drug development
(preventive)
Additional gene
manipulations
(gene editing)
Analysis of
transcription and
splicing of APP
Identification of CSF
and plasma biomarkers
NL-G-F C57BL/6J endogenous APP APPKM670/671NL,E693G,I716F
A side-by-side comparison of key factors to consider in selecting an APP mouse model for preclinical studies. Researchers should decide on a model depending on
the specific scientific or therapeutic goal.
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tau protein are not causes of AD but rather of frontotemporal
dementia with parkinsonism linked to chromosome 17 (FTDP-17).
In addition, the overexpression of multiple genes causes an
increased risk of artificial phenomena making it difficult to interpret
the results. APP-Tg mice crossbred with Mapt knockout mice exhib-
ited improvements in memory deficits and survival in APP-Tg mice,
which suggests that tau may possibly confer Ab toxicity (J20:
Roberson et al, 2007; APP23: Ittner et al, 2010). Several combina-
tions, such as APP-Tg mice crossbred with BACE1 knockout mice
(Ohno et al, 2004) or with apolipoprotein E4 (ApoE4) knock-in mice
(Fryer et al, 2005), may be more useful for specific applications.
Studies on first-generation mouse models
APP- and APP/PS-overexpressing mice exhibit key features of
amyloid pathology that have allowed them to be applied in AD
research. Although specific details of amyloid pathology such as
plaque age of onset, size and regional distribution, and Ab species
content vary depending on the line, APP-overexpressing mice reca-
pitulate aspects of cerebral Ab accumulation, including production
and deposition of Ab and associated neuroinflammation (mi-
crogliosis and astrogliosis). In some cases, downstream pathologic
consequences of Ab deposition in overexpressing mice, such as
tau hyperphosphorylation, formation of dystrophic neurites, loss of
synaptic markers, and the accumulation of BACE1 (Zhao et al,
2007), appear similar to those observed in AD. Other effects of Ab
deposition in overexpressing mice may also be relevant to AD. For
example, 5XFAD mice exhibit neuron loss and memory deficits
that are associated with amyloid pathology (Oakley et al, 2006).
Importantly, BACE1 knockout abolishes Ab deposition in 5XFAD
mice and at the same time prevents both memory deficits and
neuron loss in this and other mouse models (Ohno et al, 2007).
Thus, cerebral Ab accumulation is responsible for neuron loss and
memory deficits in these lines, rather than transgene overexpres-
sion, although effects of b-CTF overexpression cannot be ruled
out.
APP-overexpressing mice have also been useful in validating and
assessing BACE1 and c-secretase inhibition as a therapeutic strategy
for AD. BACE1 gene knockout abrogates cerebral Ab accumulation
in all APP- and APP/PS-overexpressing mice tested to date (Luo
et al, 2001, 2003; Ohno et al, 2004, 2007; Laird et al, 2005;
McConlogue et al, 2007; Rabe et al, 2011), validating BACE1 as the
major b-secretase enzyme in the brain. Subsequently, overexpress-
ing mice were used to screen small molecule inhibitors of BACE1,
some of which could reduce Ab levels in the brain and CSF by 90%
or more. Some of which have advanced to clinical trials where they
show similar Ab lowering effects in human CSF (May et al, 2015;
Neumann et al, 2015; Kennedy et al, 2016; Cebers et al, 2017).
Another application of overexpressing mice translated successfully
to humans is the preclinical testing of the anti-Ab antibody aduca-
numab. Plaque-bearing Tg2576 mice that were chronically treated
with aducanumab experienced a dose-dependent reduction of cere-
bral Ab levels by up to ~70% compared to vehicle (Sevigny et al,
2016). The mechanism of aducanumab-mediated Ab reduction
appeared to involve binding to Ab deposits in both human AD and
aged Tg2576 mouse brains stimulating microglial phagocytosis
of Ab.
Criticisms of first-generation mouse models have often focused
on the failure of c-secretase-based medications. However, mouse
work (De Strooper et al, 1999; and many follow up studies in over-
expressing models) had predicted almost all the side effects seen in
human trials, long before phase III clinical trials were halted.
Further work into the potential of tackling c-secretase in a safe
manner is based on overexpressing mice (Weggen et al, 2001) and
novel insights into more safe approaches continue (De Strooper,
2014), illustrating the utility of the overexpression paradigm for
certain types of preclinical studies specifically targeting Ab produc-
tion and Ab deposits, and possibly also for certain pathophysiolo-
gies associated with amyloid plaques such as neuroinflammation.
Limitations of first-generation mouse models
APP undergoes sequential limited proteolysis catalyzed by proteases,
collectively termed “secretases” (Fig 3A). In first-generation trans-
genic mouse models, APP overexpression therefore results in the
overproduction of various APP fragments in addition to Ab (Fig 3).
This makes it technically difficult to distinguish between the func-
tional effects of additional Ab and of other overproduced frag-
ments. It is reasonable to assume that some of the phenotypes of
the double and triple transgenic mutant mice might be of uncertain
relevance to Alzheimer’s disease. Box 1 summarizes the mutant
APP or APP/PS-overexpressing mouse models, including prospec-
tive ideas that may be experimentally validated to better consoli-
date the APP overexpression paradigm with human AD clinical
pathogenesis (Huang & Mucke, 2012; Saito et al, 2014; Palop &
Mucke, 2016).
In the absence of further validation in patient material or addi-
tional animal models in most cases, concerns remain with trans-
genic overexpression. APP overexpression for instance might induce
behavioral abnormalities prior to Ab pathology (Hsiao et al, 1996;
Mucke et al, 2000), as Ab pathology arises much earlier than overt
disease onset in humans. Apart from potential overexpression arti-
facts, it has been difficult to standardize the phenotypes of the vari-
ous models because of their construction with different promoters,
transgene constructs, and mouse strains (Webster et al, 2014; Foley
et al, 2015). In summary, further work is needed to reevaluate
published results and to be aware that some phenotypes might be
the result of APP- or APP/PS-overexpression and not part of normal
disease pathology. For instance, the extremely early lethality of
calpastatin (CAST)-deficient APP23 mice, half of which die within
10 weeks (Higuchi et al, 2012; Saito et al, 2014), clearly contradicts
the chronic progressive nature of AD. Notably, intrinsic mouse–
human differences cannot be ruled out as contributing factors as
well (Espuny-Camacho et al, 2017).
Second-generation mouse models
To overcome intrinsic drawbacks of the APP overexpression para-
digm, mouse models utilizing an App knock-in strategy were gener-
ated to overproduce pathogenic Ab such as Ab42 without
overexpressing APP. Single App knock-in mouse models were
generated in which the murine Ab sequence was humanized by
changing three amino acids that differ between mice and humans
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(G676R, F681Y, and H684R) and introduced two FAD mutations
(KM670/671NL: Swedish and I716F: Beyreuther/Iberian mutations)
into the endogenous mouse App gene (Saito et al, 2014). The identi-
fication of the Beyreuther/Iberian mutation using a phenylalanine
scan (Lichtenthaler et al, 1999) opened up the possibility for a
knock-in strategy because this particular mutation increased the
Ab42/Ab40 ratio by a factor of 30 in vitro. This mutation was subse-
quently identified as a cause for an aggressive form of FAD in Iberia
(Guerreiro et al, 2010).
Mice that carry NL-F mutations, denoted AppNL-F, exhibited
increased Ab42 production and a high Ab42/Ab40 ratio without alter-
ations in the expression levels of APP or other fragments. The
exception was that App knock-in mice produced more CTF-b and
thus sAPPb compared with wild-type mice because of the Swedish
mutation (Saito et al, 2014). Due to the increase in CTF-b and
concomitant decrease of CTF-a in the App knock-in mice, the total
amount of CTF in App knock-in mice remains the same as in wild-
type mice. To examine the effect of increased CTF-b and sAPPb in
β-secretase pathway α-secretase pathway η-secretase pathway
Overproduced proteins in
APP-overexpressing mice
 1 APP
 2 sAPPβ
 3 CTFβ
 4 Aβ
 5 AICD
 6 sAPPα
 7 CTFα
 8 P3 fragment
 9 sAPPη
 10 CTFη
 11 Aη-β
 12 Aη-α
AICD
CTFα
CTFβ
APP695
APP751
CTF-APP
AppNL-F APP23
γ-secretase
β-secretase
βα-secretase
α
η-secretase
WT
(22C11)
APP
A
B C
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CTFηCTFβ
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AICDAICD
sAPPα sAPPηsAPPβ
APP-NTF
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Figure 3. Proteolytic processing of APP in wild-type and Tg mice.
(A) APP processing by b-secretase, a-secretase, and g-secretase pathways, respectively. (B) Western blot analysis of APP and APP-derived fragments in wild-type (WT),
AppNL-F, and APP23mice indicated that only APP23mice produced APP and non-Ab APP fragments in substantial abundance. AppNL-F mice overproduce CTFb; however, AppNL
mice produce the same amount without Ab deposition (Saito et al, 2014), therefore serving as relevant negative controls. (C) Proteins that are overproduced in
APP-overexpressing mice.
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this case, AppNL mice were generated that carried only the Swedish
mutation and we confirmed that this amount of CTF-b and sAPPb
exert no effects on the pathology or cognitive function of the mice
(Saito et al, 2014; Masuda et al, 2016). The high levels of Ab42 in
AppNL-F mice led to pathological Ab deposition in the cerebral cortex
and hippocampus, which was accompanied by enhanced neuroin-
flammation, that is, infiltration of astrocytes and microglia that
surround plaques from 6 months of age. Of particular note, the
amyloid plaques in AppNL-F mice mainly consisted of pathogenic
Ab1/3pE-42 (Saido et al, 1995) in a manner similar to the brains of
AD patients, whereas the amyloid plaques in APP-Tg mice were
predominately composed of Ab1–40 and were unphysiologically
large, compared to those observed in App knock-in mice and AD
patients. A notable exception is the 5XFAD mice, which have
amyloid deposits with an over twofold greater amount of Ab1–42 as
compared to Ab1–40 (Oakley et al, 2006). Synaptic alterations in
AppNL-F mice were also identified by the loss of presynaptic synapto-
physin and postsynaptic PSD95 (Saito et al, 2014).
AppNL-F mice developed memory dysfunction at 18 months of
age as detected by the Y-maze test. In addition, Masuda et al (2016)
analyzed the knock-in mice using IntelliCage and determined that
the AppNL-F mice exhibited various cognitive dysfunctions, including
deficits in spatial memory and flexible learning, enhanced
compulsive behavior, and reduced attention performance, depend-
ing on the age and pathology of the mice (Masuda et al, 2016). App
knock-in mice that harbor a third mutation, an E693G Arctic muta-
tion (AppNL-G-F), were also generated that makes Ab more oligomer-
ization/fibrillization-prone (Cheng et al, 2007; Gessel et al, 2012),
and these mice exhibited threefold faster and greater AD pathology
and cognitive abnormalities compared with AppNL-F mice.
Reaume et al (1996) generated App knock-in mice that harbored
the Swedish mutation (K670N/M671L) with humanization of the
murine Ab sequences (AppNLh/NLh). These mice overproduced human
Ab40 and Ab42 without overexpressing APP; however, they failed to
deposit Ab in the brain at up to 22 months of age. This group subse-
quently crossbred their App knock-in mice with mutant PSEN1
knock-in mice (Flood et al, 2002; Malthankar-Phatak et al, 2012),
and the double knock-in mice successfully exhibited Ab pathology
without depending on the overexpression paradigm. The double
knock-in mice, AppNLh/NLh × PSENP264L, exhibited less aggressive
pathology compared with the double transgenic mice, likely because
of the lower expression levels of APP and PS1. These mice are
likely more difficult to use because of their double homozygous
nature but have, for reasons that are unclear, not been used exten-
sively by the community yet bear reassessment as experimental tools.
Li et al (2014) produced App knock-in mouse models using
multiple pathogenic mutations. The mice carried the Swedish
(K670N/M671L), Dutch (E693Q), and London (V717I) mutations
with the Ab sequence humanized. The Dutch mutation causes inten-
sive cerebral amyloid angiopathy (CAA) in humans, which results
in brain hemorrhage and early mortality (Levy et al, 1990; Van
Broeckhoven et al, 1990). Thus, this mutation is not a cause of
FAD; however, its discovery inspired the first identification of an
FAD mutation in the App gene (Goate et al, 1991; Hardy, 2017).
These mice alone developed minimal Ab deposits throughout life
until the authors crossbred them with PSEN1M146V knock-in mice.
The double knock-in mice exhibited an age-dependent deposition of
Ab not only in the parenchyma of the cerebral cortex but also the
cerebral vasculature in a manner similar to human CAA pathology.
Consistently, the double knock-in mice without the Dutch mutation
exhibited virtually no vascular pathology. They likely would not
have had to introduce the PSEN knock-in mice if they had used the
Beyreuther/Iberian mutation instead of the London mutation in the
mouse App gene. Nevertheless, the Dutch mutation-harboring knock-
in mice can be considered to represent relevant models for CAA.
Studies on second-generation mouse models
New studies suggest that a re-examination of previous results
obtained using first-generation mouse models with their second-
generation counterparts is good practice. We previously reported
that the activation of calpain, a calcium-activated cysteine protease,
is associated with Ab plaque formation in the brains of AD patients
and APP23 mice (Higuchi et al, 2012). Genetic ablation of calpas-
tatin (CAST), a calpain-specific inhibitor protein, exacerbated
amyloid deposition, neuroinflammation, tau phosphorylation, and
somato-dendritic atrophy. Notably, when APP transgenic mice were
crossed with CAST knockout mice, there was increased mortality
(Higuchi et al, 2012) where half of the mice died in 10 weeks for
unknown reason(s). In contrast, the double mutant AppNL-F mice
Box 1: Limitations of mutant APP- and APP/PS-overexpressing
mouse models
(i) Transgene insertion may destroy endogenous gene loci (Kuro-o
et al, 1997; Verret et al, 2012; Saito et al, 2016).
(ii) Absence of non-coding regions of the App gene precludes the
analysis of splicing of APP mRNA and transcriptional regulation
involving these gene regions (Nicolas et al, 2016).
(iii) Non-matched negative controls due to variable transgene copy
number and insertion site.
(iv) Overexpressed APP interacts unphysiologically with cellular
proteins such as kinesin via JIP-1 (Gunawardena & Goldstein,
2001; Chiba et al, 2014; Cassar & Kretzschmar, 2016; Laßek et al,
2016).
(v) Overproduced non-Ab APP fragments may interact unphysiologi-
cally with cellular proteins (Chang & Suh, 2005; Mitani et al,
2012; Nicolas & Hassan, 2014; Kerridge et al, 2015; Nhan et al,
2015; Willem et al, 2015; Xia et al, 2016). See Fig 3.
(vi) Non-specific ER stress may arise in APP/PS-overexpressing mice
(Barbero-Camps et al, 2014; Chaudhari et al, 2014; Reinhardt
et al, 2014; Borkham-Kamphorst et al, 2016; Saito et al, 2016).
(vii) Ab species may appear that are different from those found in
clinical AD brain (Saido et al, 1995; Saito et al, 2016).
(viii) Atypical region specificity of Ab pathology arises. Different Tg
mice use different promoters to drive APP transgene expression
that may affect Ab in vivo propagation (Jucker & Walker, 2013).
Höfling et al (2016) showed differences in expression level and
brain regional patterning of exogenous APP among different
APP-Tg mouse lines.
(ix) Inconsistent drug effects occurred in some cases (Duggan &
McCarthy, 2016; Ohno, 2016).
(x) Crossbreeding with other mutant mice can generate additional
artificial phenotype(s) (Higuchi et al, 2012; Saito et al, 2014).
Refer to section “Limitations of first-generation mouse models”
for details.
(xi) Crossbreeding with particular mouse strains increase premature
death in some lines (Tg2576 and TgCRND8; Carlson et al, 1997;
Chishti et al, 2001).
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crossbred with CAST knockout mice lived as long as wild-type mice,
indicating that the early lethality demonstrated in APP-Tg crossbred
with CAST knockout mice was inconsistent with the chronic nature
of AD (Saito et al, 2014). Furthermore, Ab was suggested to induce
calpain-dependent conversion of p35 to p25, a CDK5 activator,
which may play an important role in AD pathogenesis (Seo et al,
2014). AppNL-F mice crossbred with CAST knockout mice, in which
calpain is hyper activated, did not exhibit conversion of p35 to p25
despite the finding that calpastatin deficiency increases Ab amyloi-
dosis in the crossed mice (Saito et al, 2016). Thus, the conclusion
that Ab accumulation can cause p25 generation in neurons reported
in 5XFAD mice may need to be revisited, as it might be caused by a
non-specific increase in calcium (Barbero-Camps et al, 2014;
Reinhardt et al, 2014) that might be unique to APP/PS1 double
transgenic mice (Reinhardt et al, 2014), although further work is
required to draw firm conclusions. A third result where differences
between first and second-generation mouse models are evident
involved the reported down-regulation of Nav1.1, a sodium channel
expressed in PV-positive interneurons in the APP-Tg mouse line J20
and its resultant effect on epilepsy and AD phenotypes (Verret et al,
2012). In contrast, in AppNL-F mice, AppNL-F mice crossbred with
CAST knockout mice, or APP23, down-regulation of Nav1.1 was not
observed (Saito et al, 2016) although it is possible that CAST defi-
ciency makes calpain hyper activated (Higuchi et al, 2005; Takano
et al, 2005). Hypofunction of Nav1.1 has been also observed in
other mouse models such as Tg2576, TgCRND8, and BACE1 trans-
genic mice (Kim et al, 2007; Corbett et al, 2013; Hamm et al, 2017),
and the effect of amyloid on Nav1.1 expression and its phenotypic
consequences in AD mouse models should continue to be reviewed
and validated in future studies.
Several basic findings using the second-generation mouse models
have advanced the basic biology of AD. Hama et al (2015) devel-
oped a new sorbitol-based optical clearing method referred to as
ScaleS that preserves the cellular structure of the tissue and
proteins, including their immunochemical epitopes, enabling a 3D
analysis of plaque deposition. AppNL-F mice treated with ScaleS
allowed quantitative visualization of Ab in an entire hemisphere,
mapping of the 3D network of amyloid plaques in association with
the vascular structure, and tracking of single plaques via successive
light microscopy (LM) and electron microscopy (EM) observations.
3D images of microglial activation during amyloidosis of AppNL-F
brains demonstrated that microglia association and active inflamma-
tion occur at an early stage of plaque formation. Such clearing meth-
ods combined with AD mouse models enable analysis of the degree
of Ab burden in larger brain volumes compared with conventional
immunohistochemistry and are also applicable for the verification of
immunotherapy (Sevigny et al, 2016) by visualizing therapeutic
anti-Ab antibody binding to regional amyloid in situ.
One proposed mechanism for memory loss in AD is the destabi-
lization of mushroom-shaped postsynaptic spines, which may play
an important role in memory storage. In accord, several reports indi-
cate a reduction in mushroom spines in AD brain. In AppNL-F mice,
Zhang et al (2015) demonstrated that hippocampal mushroom
spines are lost and the STIM2 (stromal interaction molecule 2)-nSOC
(neuronal store-operated calcium entry) pathway is altered as early
as 3 months of age in a time-dependent manner. The authors
demonstrate the relationship between extracellular Ab42 and spine
loss concluding that Ab42-induced hyperactivation of mGluR5 and
the subsequent overload of ER Ca2+ signaling likely represent the
main cause for mushroom spine loss in App knock-in mice. More-
over, an sSOC-positive modulator NSN21778 recovered the reduc-
tion of mushroom spines and memory deficits via activation of
transient receptor potential canonical 6 in App knock-in mice
(Zhang et al, 2016).
The orphan G protein (heterotrimeric guanine nucleotide-binding
protein)-coupled receptor (GPCR) GPR3 is reported to regulate c-
secretase activity and Ab generation without affecting Notch recep-
tor proteolysis (Thathiah et al, 2009). Recently, Huang et al (2015)
demonstrated that genetic deletion of GPR3 reduced amyloid pathol-
ogy in the brains of the App knock-in models, as well as the APP-Tg
and APP/PS1-Tg models. However, a reduction in the Ab42/Ab40
ratio following a genetic deficiency of GPR3 was detectable only in
AppNL-F/NL-F mice and not in the transgenic mice. In addition, they
demonstrated that both the number and volume of amyloid plaques
in AppNL-F/NL-F mice crossbred with Gpr3/ mice were decreased
compared with single AppNL-F/NL-F (Gpr3+/+) mice using 3D analysis
with another clearing technique, CLARITY. These findings demon-
strate that second-generation mouse models can be used to evaluate
the effect of new therapeutic targets on Ab pathology.
BACE1 activity is up-regulated in AD patients, after Ab deposi-
tion, and in traumatic brain injury (Rossner et al, 2006). Kizuka et al
(2015) hypothesized that bisecting N-acetylglucosamine (GlcNAc)
stabilizes BACE1 protein during oxidative stress, which results in an
increase in Ab generation. In a more recent paper, they demonstrated
the up-regulation of BACE1 protein and the level of bisecting GlcNAc
in AppNL-G-F/NL-G-F mouse brains, which was accompanied by an
accumulation of oxidative damage (Kizuka et al, 2016).
Recently, the App knock-in mice were used to refute the hypothe-
sis that the new Alzheimer candidate gene PLD3 (Cruchaga et al,
2014) was involved in APP processing. Crossing of Pld3 deficient
mice with App knock-in mice demonstrated that there was no
modulation of Ab plaque or APP cleavage in these mice (Fazzari
et al, 2017)
Limitations of second-generation mouse models
Like single APP overexpression mice, the knock-in mice do not
exhibit tau pathology or neurodegeneration. This finding suggests
that Ab pathology may account, at least in part, for the cognitive
dysfunction in AD via disturbances in neuronal activities because
Zhang et al 2015 identified a reduction of mushroom spines, distin-
guishing spine structure at excitatory synapses, in the early stage in
these mice. However, the Ab-induced memory failure alone might
be insufficient to explain all symptoms of AD patients because
tauopathy-accompanying irreversible neurodegeneration has previ-
ously occurred at disease onset even in FAD-mutation carriers
(Bateman et al, 2012). Therefore, App knock-in mice should be
considered “models of preclinical AD”. A summary of features and
limitations in App knock-in mice is shown in Box 2.
The absence of tauopathy and neurodegeneration in these mice,
which live less than 3 years, may be simply a matter of AD time
course because it requires more than two decades for Ab amyloido-
sis to induce cortical tauopathy and neurodegeneration in humans
(Bateman et al, 2012). To address these questions, further genetic
manipulation to study the connection between Ab pathology and
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tauopathy/neurodegeneration will be required. There are only three
splice variants of tau (Mapt gene product) in adult mouse brain
whereas there are six in humans. We therefore have generated
human tau knock-in mice, in which all the exons and introns of
murine Mapt gene have been humanized (Saido et al, 2015). The
mice are available to the research community from RIKEN. Other
genes should not need to be humanized because overexpression of
frontotemporal dementia with parkinsonism (FTDP) mutation-
carrying human tau is sufficient to reconstitute tauopathy composed
of Neurofibrillary tangles (NFTs) and neurodegeneration (Lewis
et al, 2000).
Biomarkers for the diagnosis and prognosis of preclinical AD will
not only reduce the cost but also shorten the time necessary for drug
development. AppNL-F and AppNL-G-F mice are the only single knock-
in models that develop Ab pathology and memory deficits.
However, the presence of multiple mutations in the App gene, not
observed in human patients, could in principle interact with each
other in some cases that may not accurately represent clinical AD
(Box 2). Thus, AppNL-F mice are suitable for analyzing the mecha-
nisms that affect preclinical Ab deposition compared with AppNL-G-F
that may be more useful for analyzing the mechanisms that alter
downstream cascades.
Despite these potential drawbacks, App knock-in mice may be
useful as preclinical AD models for a number of purposes including
(i) identification of biomarker(s) for preclinical AD, (ii) identifi-
cation of molecules that evoke tauopathy in an Ab pathology-
dependent manner, (iii) preclinical studies of preventive medicine(s),
(iv) a platform for the generation of improved AD model(s) by
crossbreeding with appropriate mutant mice (Table 1), and (v) to
study the cellular phase of Alzheimer’s disease (De Strooper &
Karran, 2016), including the progressive response of vascular,
astroglia, oligodendrocyte, and microglial cell populations upon
amyloid stress. A distinct advantage is that expression from an
endogenous promoter ensures that responses are not directed to
cells that artifactually overexpress APP.
Future perspectives on AD mouse modeling
Previous first-generation transgenic mouse models have made
substantial contributions to our understanding of AD pathology.
Many of these studies carried out with the best available mouse
lines at the time have advanced the understanding of AD. The new
second-generation mouse lines solve some of the previous limita-
tions and point the way to future third generation models. Until
such next generation models become available, studies that investi-
gate the interface of results from first- and second-generation
models will continue to reveal discrepancies and may in some cases
indicate that findings from previous AD models may in part be a
consequence of overexpression artifacts. Sorting out the clinically
relevant phenotypes and mechanisms will require years of work
with all the models but we urge AD researchers to remain vigilant
and not to assume textbook status for any previous findings without
extensive validation using the most appropriate mouse lines. We
further emphasize that preclinical studies, including immunother-
apy, may benefit from a re-examination with new models to identify
drug candidates for the preclinical prevention of earlier AD
symptoms.
Species differences between rodents and humans in terms of
neuroanatomy, genetics, and behaviors are also critical to control
(Emes et al, 2003; Molna´r & Clowry, 2012; Kaas, 2013; Nithianan-
tharajah & Grant, 2013). Key molecules in AD such as Ab, tau, and
ApoE are different between mice and humans in their sequences,
pathogenicity or number of isoforms expressed. In addition,
immune systems in the brain also differ between mice and humans
in certain aspects such as the proportion of microglial phenotypes,
or the expression pattern of inflammation-related genes (reviewed
by Franco Bocanegra et al, 2017). The development of induced
pluripotent stem cells (iPSCs) from AD patients can help to address
species differences (Mungenast et al, 2016; Sullivan & Young-
Pearse, 2017). Recently, a novel chimeric AD mouse model was
developed by transplanting human PSCs into AD mouse brain,
showing pathological changes in tau and neurodegeneration in
human neurons (Espuny-Camacho et al, 2017). Furthermore, to
leverage species differences for near-clinical studies, we are generat-
ing non-human primate models of AD (Okano et al, 2016) with
more similarity to humans that could reduce species barriers and
limit the time and cost of drug development.
AD research can benefit from modern views in the fields of
immunology and cancer progression. Cancer stem cells arise in
human bodies every day, but fail to develop into cancer in most
cases because of cancer immunity (Yarchoan et al, 2017; Yeo &
Box 2: Limitations of single App knock-in mouse model and
potential solutions
(i) All the lines carry Swedish mutations (NL), which may exhibit dif-
ferent sensitivity to b-secretase inhibitors from the wild-type lines
(KM). This is however easy to fix by converting NL to KM by gene
editing, which cannot be applied to the APP-overexpressing mice.
(ii) The Swedish mutation causes an increase of CTF-b and concomi-
tant reduction of CTF-a. Consequently, total CTF levels
(CTF-b + CTF-a) remain unchanged. If CTF-b possesses particular
biological or pathological functions, this may cause artifacts. Still,
the amount of CTF-b in single App knock-in mice is much smaller
than that in APP-overexpressing mice.
(iii) The knock-in mice possess two or three independent FAD muta-
tions in the App gene. There is no evidence for an interaction
between the Swedish mutation and Beyreuther/Iberian muta-
tions, but the Arctic mutation increases CTFs (CTF-b + CTF-a) by
50% by unknown mechanisms (T Saito & TC Saido, unpublished;
Cheng et al, 2004) and results in an unnatural Ab conformation.
It is important to perform delipidation pretreatment for the anal-
ysis of CTFs (Sato et al, 2003; Saito et al, 2014).
(iv) The negative control mice, AppNL, accumulate no Ab throughout
life, but appear to induce minor microgliosis specifically in
hippocampus and compulsive behavior (Masuda et al, 2016).
(v) The knock-in mice are used in a homozygous status, in order to
achieve early pathology and to remove murine Ab. It is advised to
backcross them with the original line, B6/J, occasionally, to protect
the mice from accumulating de novo mutations that could cause
recessive defects.
(vi) APP may behave different from human APP because the App gene
except for part of intron 15–17 is a murine sequence. For example,
KPI domain-containing APP variants are not expressed in mouse
brain unlike in human brain (Saito et al, 2014). Therefore, App
knock-in mice may not be suitable for addressing the properties
of KPI domain-containing APP variants in endothelial cells, since
these variants are expressed mostly in endothelial cells (Kitazume
et al, 2010).
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Angeli, 2017; Fig 4). We can draw an analogy between cancer
immunity and AD protective mechanism(s) in the brain, which can
maintain cognition essentially unaffected for more than two decades
after the initial deposition of Ab. If we could identify the molecules
responsible for this protection, we should be able to facilitate
studies of the major AD pathologies in mice by knocking out or
modifying the corresponding genes. In the progressive systemic
dysfunction that characterizes the cellular phase of AD, many types
of cells are involved with complex feedback and feedforward
responses at different disease stages.
The emerging insight that AD is a multidimensional and multi-
cellular process will require more integrated and complex forms of
analysis (Tarasoff-Conway et al, 2015; De Strooper & Karran,
2016). Knock-in animals are most suitable to study these processes
with target genes that are expressed in the correct cell types, with
appropriate timing and amounts under the control of endogenous
promoters. In addition, a number of common variants associated
with LOAD have been identified in genes that participate in Ab
clearance or neuroinflammation in genome-wide association stud-
ies (GWAS; Rosenberg et al, 2016; Naj et al, 2017). Effects of these
variants can be precisely assessed by additional gene manipula-
tions in App knock-in mice. Both crossbreeding App knock-in mice
with other existing mutants and gene editing, which utilizes novel
techniques, such as transcription activator-like effector nuclease
(TALEN) and clustered regularly interspaced short palindromic
repeat (CRISPR)/Cas9 will reveal new mechanisms of Ab pathol-
ogy (Lee et al, 2016).
In conclusion, major steps to improve mouse models for AD
are underway. While first-generation models will remain impor-
tant and relevant for AD research, the second-generation mice
solve some of the limitations of previous models for both basic
and preclinical studies of AD. Standardization and sharing of
disease models is essential for the objective interpretation of data,
and the second-generation mice can serve as one of the important
baseline models for mechanisms of Ab pathology obtained in
different laboratories or under different conditions. However,
every mouse model has limitations, and further side-by-side
comparisons between App knock-in mice, APP-overexpressing
mice, and other models and observations from human AD
patients are required to move toward effective treatments. AD
researchers can and should develop an ethic of sharing and
comparing data and tools, carefully selecting the most suitable
models for their purposes, and analyzing the data with an eye
toward maximizing replication. To conquer AD as soon as possible,
such collaboration ethics on a global scale will maximize the
speed of drug development.
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